PMID- 23111179
OWN - NLM
STAT- MEDLINE
DCOM- 20130314
LR  - 20220331
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 155
IP  - 2
DP  - 2013 Feb
TI  - Intravitreal bevacizumab for macular complications from retinal arterial 
      macroaneurysms.
PG  - 287-294.e1
LID - S0002-9394(12)00558-2 [pii]
LID - 10.1016/j.ajo.2012.07.029 [doi]
AB  - PURPOSE: To evaluate the anatomic and functional results of the treatment with 
      intravitreal bevacizumab in complicated retinal arterial macroaneurysm (RAM). 
      DESIGN: A multicenter interventional, prospective, nonrandomized study. METHODS: 
      Thirty-eight macroaneurysms of 37 patients with foveal complications were 
      evaluated. All patients underwent a comprehensive ophthalmologic examination, 
      fluorescein angiography (FA), and spectral-domain optical coherence tomography 
      (SD OCT) examination. Each patient underwent 3 monthly injections of bevacizumab 
      1.25 mg/0.05 mL; 3 follow-up visits were planned at week 2, 6, and 12. RESULTS: 
      Both best-corrected visual acuity (BCVA), expressed in logarithm of minimal angle 
      of resolution (logMAR), and central retinal thickness (CRT) significantly 
      improved during the follow-up visits (0.57 +/- 0.21 vs 0.41 +/- 0.15 vs 0.23 +/- 0.13 
      vs 0.09 +/- 0.10 and 520.38 +/- 191.05 vs 396.24 +/- 136.18 vs 283.86 +/- 71.87 vs 214.84 
      +/- 26.86, respectively, Friedman test P < .0001 for all variables). At 6 weeks of 
      follow-up, FA showed complete closure of the RAM in 36 of 38 cases (94.7%). Four 
      weeks following the third injection, the macular edema had completely resolved 
      and hard exudates regressed slowly in 100% of patients. CONCLUSIONS: Intravitreal 
      bevacizumab is an effective therapy for complicated RAM, quickly improving BCVA 
      and CRT. Anti-vascular endothelial growth factor (VEGF) drugs might actively 
      close the involved pathologically permeabilized retinal artery and normalize the 
      vessel wall formation by localized inhibition of VEGF.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Pichi, Francesco
AU  - Pichi F
AD  - San Giuseppe Hospital, University Eye Clinic, Milan, Italy. 
      ilmiticopicchio@gmail.com
FAU - Morara, Mariachiara
AU  - Morara M
FAU - Torrazza, Carlo
AU  - Torrazza C
FAU - Manzi, Gianluigi
AU  - Manzi G
FAU - Alkabes, Micol
AU  - Alkabes M
FAU - Balducci, Nicole
AU  - Balducci N
FAU - Vitale, Lucia
AU  - Vitale L
FAU - Lembo, Andrea
AU  - Lembo A
FAU - Ciardella, Antonio P
AU  - Ciardella AP
FAU - Nucci, Paolo
AU  - Nucci P
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20121027
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
CIN - Am J Ophthalmol. 2013 Apr;155(4):774-5. PMID: 23521902
CIN - Am J Ophthalmol. 2013 Apr;155(4):774. PMID: 23521903
MH  - Aged
MH  - Aged, 80 and over
MH  - Aneurysm/diagnosis/*drug therapy
MH  - Angiogenesis Inhibitors/administration & dosage/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use
MH  - Bevacizumab
MH  - Exudates and Transudates
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Retinal Artery/*drug effects/pathology
MH  - Retinal Diseases/diagnosis/*drug therapy
MH  - Retinal Hemorrhage/diagnosis/drug therapy
MH  - Subretinal Fluid
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity/physiology
EDAT- 2012/11/01 06:00
MHDA- 2013/03/15 06:00
CRDT- 2012/11/01 06:00
PHST- 2012/04/19 00:00 [received]
PHST- 2012/07/27 00:00 [revised]
PHST- 2012/07/31 00:00 [accepted]
PHST- 2012/11/01 06:00 [entrez]
PHST- 2012/11/01 06:00 [pubmed]
PHST- 2013/03/15 06:00 [medline]
AID - S0002-9394(12)00558-2 [pii]
AID - 10.1016/j.ajo.2012.07.029 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2013 Feb;155(2):287-294.e1. doi: 10.1016/j.ajo.2012.07.029. Epub 
      2012 Oct 27.